Trials / Completed
CompletedNCT04314817
Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Any drug used to treat Covid-19 | lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date. |
Timeline
- Start date
- 2020-03-17
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
- First posted
- 2020-03-19
- Last updated
- 2023-04-21
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04314817. Inclusion in this directory is not an endorsement.